This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
In a recent phase 3 trial, SBRT led to similar tumor control and survival outcomes compared with hypofractionated conventional radiotherapy in patients with stage I NSCLC.
Medscape Medical News